Merck (MRK) CMO Chirfi Guindo disposes of 10,000 common shares

Rhea-AI Filing Summary

Merck & Co., Inc. Chief Marketing Officer Chirfi Guindo reported selling 10,000 shares of Merck common stock on 02/09/2026. The sale was executed at a weighted average price of $118.4101 per share, with individual trades ranging from $118.4000 to $118.4502. After this transaction, Guindo beneficially owns 70,615.127 shares of Merck common stock directly.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Guindo Chirfi

(Last) (First) (Middle)

MERCK & CO., INC.

126 EAST LINCOLN AVENUE

(Street)

RAHWAY NJ 07065

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Merck & Co., Inc. [ MRK ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Marketing Officer

3. Date of Earliest Transaction (Month/Day/Year)
02/09/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/09/2026		S		10,000	D	$118.4101(1)	70,615.127	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $118.4000 to $118.4502, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote.

	/s/ Kelly Grez, as attorney-in-fact for Mr. Chirfi Guindo	02/09/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Merck (MRK) report for Chirfi Guindo?

Merck reported that Chief Marketing Officer Chirfi Guindo sold 10,000 shares of common stock. The transaction occurred on 02/09/2026 and was reported on a Form 4 insider trading filing with the Securities and Exchange Commission.

At what price did Merck (MRK) CMO Chirfi Guindo sell shares?

Chirfi Guindo sold the shares at a weighted average price of $118.4101 per share. Individual trades were executed in a price range from $118.4000 to $118.4502, according to the transaction footnote in the Form 4 filing.

How many Merck (MRK) shares does Chirfi Guindo own after the sale?

Following the reported sale, Chirfi Guindo beneficially owns 70,615.127 shares of Merck common stock. The Form 4 indicates these shares are held with direct ownership, reflecting Guindo’s remaining stake after disposing of 10,000 shares.

What role does Chirfi Guindo hold at Merck (MRK)?

Chirfi Guindo is identified as Chief Marketing Officer of Merck & Co., Inc. in the Form 4. The filing classifies Guindo as an officer of the issuer, rather than a director or 10% beneficial owner of Merck common stock.

Was the Merck (MRK) insider sale executed in a single trade or multiple trades?

The filing notes that the 10,000 shares were sold in multiple transactions. Prices ranged from $118.4000 to $118.4502, with the reported $118.4101 representing a weighted average across all individual sale executions.

Does the Merck (MRK) Form 4 provide details on each individual trade price?

The Form 4 discloses only a weighted average price and price range, not each trade. However, the footnote states the reporting person will provide full trade-by-trade price information to Merck, any security holder, or SEC staff upon request.